Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
Why Is WidePoint Corporation (WYY) Stock Down -56.28% Today?

Why Is WidePoint Corporation (WYY) Stock Down -56.28% Today?

Key Takeaways

  • Shares plunged roughly 56% in Thursday's session, falling from a prior close of $11.07 to about $4.84.
  • The sell-off was driven primarily by a heavily dilutive equity offering, with trading volume surging well beyond normal levels.
  • The decline marks a sharp valuation reset after a prolonged rally fueled by government contract momentum.
  • Secondary pressure came from profit-taking and uncertainty over the timing of major contract awards.
  • Traders are now watching offering details, contract updates, and the next earnings report for direction.

Opening Summary

WYY — WidePoint Corporation, a Fairfax, Virginia-based provider of Technology Management as a Service (TMaaS) and cybersecurity solutions for government and enterprise clients — suffered one of its sharpest single-day declines on record Thursday. The stock tumbled approximately 56.28%, falling from a previous session close of $11.07 to an intraday level near $4.84. The move erased a substantial portion of the company's year-to-date gains, which had exceeded 100% just a day earlier, and came on unusually heavy volume, signaling a decisive repricing driven by a dilutive capital raise rather than a deterioration in underlying operations.

Dilutive Equity Offering

The primary catalyst behind the collapse appears to be a dilutive share offering. WidePoint had registered an at-the-market equity facility of up to $15.5 million, and the session's surge in volume — with millions of shares changing hands versus a typical daily average in the low hundreds of thousands — is consistent with newly issued shares being sold into the market at a significant discount to the prior trading price. For a micro-cap company with roughly 10 million shares outstanding, a capital raise of this scale materially expands the share count, diluting existing shareholders and mechanically pressuring the stock price. Markets reacted decisively, sending the shares lower as investors absorbed the supply.

Valuation Reset After a Steep Rally

WidePoint's decline was magnified by how far the stock had already run. WYY had surged more than 100% year to date and roughly 112% over the trailing 52 weeks, propelled by investor enthusiasm over a potential $3.1 billion contract ceiling tied to the Department of Homeland Security's CWMS program and its selection for NASA's SEWP VI government-wide acquisition vehicle. That optimism left the shares trading at a premium valuation with limited earnings support — the company's profitability remains thin despite growing revenue. A dilutive financing event gave investors a reason to re-rate the stock closer to its fundamental value, amplifying the sell-off well beyond what a typical news-driven pullback would look like.

Government Contract Uncertainty

Compounding the pressure, WidePoint's largest pending opportunity remains unresolved. Management has publicly acknowledged that the timeline for the CWMS 3.0 award has been pushed back by government shutdowns, funding disruptions, and leadership changes at the Department of Homeland Security. While the company continues to operate under contract extensions, the lack of a definitive award has left some investors questioning whether the contract ceiling will translate into the sustained, margin-accretive revenue that the rally anticipated. That uncertainty made the stock more vulnerable to the financing news, as holders who had bet on imminent contract clarity moved to reduce risk.

Market Context and Trading Activity

The move was decidedly stock-specific rather than a reflection of the broader market. Major U.S. equity indices were little changed to modestly higher Thursday, meaning WYY diverged sharply from the tape. Volume was dramatically elevated — roughly an order of magnitude above recent averages — confirming heavy institutional and shareholder selling tied to the offering. The plunge took the stock through its 50-day moving average and toward levels last seen before the summer's contract-driven surge, leaving technical traders to reassess support in the low single digits. The stock's high beta, historically elevated relative to the market, contributed to the outsized magnitude of the move.

What Comes Next for WYY

Looking ahead, investors will focus on the terms and completion of the equity offering, including how many shares were issued and at what price, to gauge the extent of dilution. The company's next quarterly earnings report is expected around mid-November, providing an update on revenue growth, margins, and cash flow. Developments on the CWMS 3.0 contract and the ramp of its SaaS carrier agreement remain key swing factors, as does management's ability to convert its government contract pipeline into profitable, recurring revenue. Risks include further equity issuance, continued contract delays, and thin operating margins, while any definitive award or improved profitability could help stabilize the shares.

Trending AI Robots

For traders seeking a more systematic approach to navigating volatile small-cap moves like this one, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the top performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, allowing users to explore approaches aligned with their own objectives. Explore the Trending AI Robots to see which automated strategies are leading the market today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WYY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


WYY in upward trend: price rose above 50-day moving average on September 14, 2026

WYY moved above its 50-day moving average on September 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on August 28, 2026. You may want to consider a long position or call options on WYY as a result. In 73 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for WYY just turned positive on August 27, 2026. Looking at past instances where WYY's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

The 10-day moving average for WYY crossed bullishly above the 50-day moving average on September 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +14.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where WYY advanced for three days, in 215 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 172 of 213 cases where WYY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for WYY moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 28 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WYY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

WYY broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. WYY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WYY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.479) is normal, around the industry mean (7.623). P/E Ratio (65.789) is within average values for comparable stocks, (69.238). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (2.298). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.774) is also within normal values, averaging (145.217).

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 8.85B. The market cap for tickers in the group ranges from 100 to 213.92B. IBM holds the highest valuation in this group at 213.92B. The lowest valued company is ARSC at 100.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was -2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 25%. INOD experienced the highest price growth at 26%, while VEEA experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was -19% and the average quarterly volume growth was -70%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 72
Profit Risk Rating: 92
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
WYY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of information technology solutions to the government and commercial markets

Industry InformationTechnologyServices

Industry
Data Processing Services
Address
11250 Waples Mill Road
Phone
+1 703 349-2577
Employees
247
Web
https://www.widepoint.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.